Saturday, January 26, 2008

CJD HGH BODY SNATCHERS

Saturday, January 26, 2008 CJD HGH BODY SNATCHERS HORMONE DRUGS LED TO CJD DEATH

09:00 - 26 January 2008

A Young mum died from the human form of mad cow disease after taking growth hormones as a child, an inquest heard.Ann Davies, known to friends and family as Anne, was diagnosed with the devastating Creutzfeld-Jakob-Disease in November 2004 after receiving lengthy treatment in the 1970s to help her grow.

She died on March 7 last year, aged 29.

The former Bishop's Cleeve pupil developed the disease after taking pituitary growth hormones extracted from humans before the drugs were withdrawn in 1985.

Family doctor Dr Neil Fraser, who had known her since 1984 when he treated her at Birmingham Children's Hospital, said she suffered congenital growth hormone deficiency shortly after birth.

He told the inquest she started the injections, which were administered three times a week, in 1980.

"The potential transmission of CJD from pituitary growth hormone was known in the 1970s," said Dr Fraser.

"It was thought the change in the method of extraction of the growth hormone from the pituitary glands would remove the agent causing CJD.

"While Ann would only have received this pituitary growth hormone prepared by this later method, her case and that of many others has sadly proved this not to be the case.

"I have no doubt Ann's CJD was caused by the transmission of the human form of the disease by growth hormone extracted from the pituitary gland."

A post mortem revealed the cause of death was CJD.

Recording a verdict of accidental death, Gloucestershire coroner Alan Crickmore, said: "I am satisfied from the evidence I've heard that from 1979 to 86 she did receive treatment designed to assist her in combating her lack of growth.

"Unfortunately she also received the chemicals which developed the disease. If she hadn't had the injections, she wouldn't have developed the disease."

CJD causes memory loss, personality changes and a loss of coordination. Sufferers usually die within six months of symptoms.

http://www.thisisgloucestershire.co.uk/displayNode.jsp?nodeId=231771&command=displayContent&sourceNode=231774&contentPK=19671559&folderPk=108867&pNodeId=231888

Greetings,

I am very sorry for the senseless loss of Anne.

Please accept my sincere condolences.

I cannot accept ;

Verdict: Accident. ???

in my opinion, it was nothing less than corporate and political homicide i.e. FOR PROFIT $$$ but in the eyes of the ones responsible, it was another calculated, expendable death, due to the incubation period, parties responsible knew they could get away with it. ...tss

SENATE

snip...

Mr Stachlewski—Dr Tony Adams started saying what I think is a fairly important set of issues regarding the perceptions of the government at that particular time. That program was taped in 1994. The significance of his statements speak for themselves. However, he goes on to say a number of other things apart from the fact that pituitary hormone patients, certainly those in the HGH area, were guineapigs. ‘Medical misadventure’ is used as a term and he goes on to talk about a variety of other areas. I think the important thing here to stress is that, when you talk about people being guineapigs, it is a rather intriguing little exercise, particularly since they are human guineapigs. I think Dr Tony Adams at that particular stage said what we all thought was the case—that it was an experimental program—and Allars subsequently put that into her paper and into her report.

snip...

In our particular submission to Allars we also looked at the independence of each of the committee structures so that there was seen to be independence from the government. The reason for suggesting that was that the government was involved, in the first instance, in the program, its development and administration, et cetera. It was also involved in the various committees. Dr Tony Adams goes on to say, and I quote from the transcript of the video tape:

They were over enthusiastic—

‘They’ being the doctors—

so some of the such guidelines that were in place were either ignored or fudged. To go over it again: the question was asked:

So patients welfare was sacrificed?

The answer was:

Unfortunately yes.

Tony Adams also said:

Here was a situation that should have been corrected earlier than it was and people concerned both in Government and in the Committees who were handing out the hormones were derelict in their duty in not stopping it sooner.

snip...

It is a fact the pituitary glands were not donated, so no record of the cadavers was ever kept. Ergo there is no way anyone can now go back and find out where the CJD originated. This is reprehensible. In our society grave robbing is illegal, is it not? For what they did was, indeed, grave robbing. When you take something from a dead body that you have not received permission for from the next of kin, and then proceed to exchange money for said body part, what else can it be called? When you harvest a portion of the brain from a patient who resides in a mental institution, when you fail to tell the recipients that the procedure is experimental and falsely state that the glands were donated and assure them of the product’s safety, as well as fail to inform of other safer procedures, isn’t that the grossest of neglect?

My safety and the safety of all the other victims in this case were never adequately protected at any time. The definition of ‘victim’ is a person who is harmed by or made to suffer from an act, circumstance, agency or condition. What is a person who is tricked, swindled or taken advantage of? A dupe. That is what I and all of my fellow victims are—dupes. We trusted and believed what we were told by those whom it is ingrained in us from childhood to trust—our doctors.

snip.

Mr Glen—Both of those are very good questions. If I may deal with the second one first, the situation—put very briefly—regarding the UK trial, which I was at myself so I am able to expand on that, was that the Hon. Mr Justice Morland ruled that the Department of Health in Britain was not negligent in relation to the deaths of those who had died from CJD before 1 July 1977 upon the basis that the state of knowledge prior to that date did not amount to negligence. For all those who were treated after that date, the government was liable, and for those families who had lost loved ones to CJD as a result of human growth hormone—one must remember that there is no HPG outside Australia— the government was liable. We are not talking about psychiatric injury; we are talking about deaths. Our clients were advised of that by way of letter when we arrived back from the UK. I have got the letter here. On 14 June 1996 we wrote a detailed letter to our clients. It opens with these words, ‘We now report to you on our trip to the UK and the USA,’ and it was a three-page letter. We did not know the result of the decision then, of course, because the judge had reserved his decision. Senator, does that answer the second part of your question?

Senator LIGHTFOOT—If you are saying that, yes, your clients were notified. Mr Glen—Yes, we did notify them then. After the decision had been announced— I think it was in August 1996—we notified them of the decision. Senator LIGHTFOOT—Shortly after the decision had been brought down? Mr Glen—That is right. We understand that parts of that judgment of the Hon. Mr Justice Morland are now under appeal by the plaintiff and the defendants. The first part of your question is also a good question because we believe the strongest part of our case against the government was on the issue of negligence in the running of the program as per the Allars report—that they owed our clients a duty of care and that there was a subsequent breach of that duty. The most difficult part of our claim was establishing psychiatric injury as a result of the government’s negligence. That, as I have indicated before, involved novel questions. Senator LIGHTFOOT—Have you advised your clients to accept damages for psychiatric injury? Mr Glen—Have we advised our clients? Senator LIGHTFOOT—Yes. Mr Glen—Our clients have been offered nothing for psychiatric injury. Senator LIGHTFOOT—But that was not my question.

snip...see full text 76 pages ;

http://www.aph.gov.au/hansard/senate/commttee/s9975723.pdf


CJD (Human Growth Hormone) Between 1959 and May 1985, 1800 children were treated under the National Human Growth Hormone Hgh) programme. There is a risk of CJD associated with some of the treatment.

---------------------------------------------------------------------------- ----

Case study: Background Some 1,800 children were treated under the National Human Growth Hormone (Hgh) programme. This ran from 1959 until May 1985 when Hgh was banned following the death of a recipient in England and two deaths in America from Creutzfeldt Jakob Disease (CJD).

The programme was initially under the control of the Medical Research Council, but from 1977 onwards was run by the Department of Health. It set out to restore growth patterns in children who would not otherwise have reached normal stature.

After the first death here, the programme was immediately stopped following consultation among the clinicians involved, and Hgh was replaced by a synthetic version. The human based product had been prepared from pituitary glands recovered from cadavers - pituitaries were routinely collected at post-mortem examination in mortuaries and it is estimated that over 960,000 pituitaries were harvested to make Hgh and/or other pituitary derived hormone treatments.

In 1992 the news generally broke that there was a risk of CJD associated with Hgh treatment, as the number of deaths rose. Sadly, we are now aware of at least 42 deaths from CJD in this group.

---------------------------------------------------------------------------- ----

Action As the numbers of CJD deaths began to rise, IM was first instructed to investigate matters in the early 1990s. We helped campaign with the families for a public inquiry but this was never granted, and as a last resort to try and find out what had happened and why, IM launched the Creutzfeldt Jakob Disease litigation in 1993.

This was divided into two groups - Group A on behalf of the victims of CJD and their families, and Group B for psychiatric injury claims for the 'worried well', who can only be told they have received potentially contaminated Hgh which may lead to this invariably fatal, dreadful neurological condition, for which there is still no test and no cure.

IM was one of the two firms on the Legal Aid Steering Committee running the litigation, and this was the first Legal Aid contract granted for a group action. This was also the first action brought in relation to any Hgh programmes anywhere in the world and the first successful pharmaceutical group action ever fought in the UK.

---------------------------------------------------------------------------- ----

Result Following the generic trial in 1996, Mr Justice Morland held that the Department of Health had been negligent for failing to suspend the Hgh programme as from July 1977.

Initially, the Judge's finding only covered new entrants on to the programme. IM successfully argued before the Court of Appeal in 1997 that the Judge should also be asked to consider those already receiving Hgh. The Judge subsequently accepted evidence from various clinicians, who confirmed they would also have suspended treatment for those already involved. This finding meant we were able to obtain compensation for the vast majority of families of those who had died, where either all or the majority of treatment had taken place after 1st July 1977.

The Department of Health agreed they would compensate any after-occurring cases of CJD which fell within the terms of the Judgment, and IM continue to be involved with most of those who develop this awful disease.

We also won the right to put forward claims for psychiatric injury for Group B, and the trial of six lead cases came before the Court in 1998. Subject to the proof of a frank psychiatric reaction to the awareness of the risk of CJD, these cases were also successful for those treated after 1st July 1977 with potentially contaminated Hgh. (A number of different preparation methods were used during the programme; more modern preparations were used from around mid-1982 and do not seem to be implicated in the crisis).

In what was the first case of its kind, Mr Justice Morland ruled the Claimants had suffered psychiatric injury as a result of being told they may develop CJD, and that their fears were rational. This success paved the way for a further 40 people to pursue psychiatric claims within the litigation, as well as numerous 'afteroccurring' claims.

All the lead psychiatric cases were successful and provided a range of cases for the Court. The Claimants were awarded between £3,500 and £300,000, including, in one case, the largest Smith v Manchester award (for disadvantage on the labour market) made at that time.

CJD has a long incubation period; new cases of CJD are regularly reported. Provisions have been made within the Queen's Bench Division of the High Court to accommodate claims for the foreseeable future.

For more information call 0870 1500 100 or drop us a line

http://www.irwinmitchell.com/RecentWork/CJDlitigation.htm


BMJ 1996;312:1057 (27 April)

News Trial begins into victims of CJD growth hormone The families of eight young people who died from Creutzfeldt-Jakob Disease (CJD) after being injected with human growth hormone as children began a test case against the Department of Health and the Medical Research Council in the High Court in London last week. The eight victims were among 17 people aged between 20 and 34 who developed the disease after treatment with human growth hormone between 1959 and 1985. Sixteen have died and the seventeenth is dying.

http://www.bmj.com/cgi/content/full/312/7038/1057


Creutzfeldt-Jakob Disease, CJD Support Group for short statured children of the 1970's and 1980's. Recommendations for Unapproved/Unregistered recipiants

http://mc2.vicnet.net.au/home/shortboys/web/cjdaustralia.html


Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States

http://cjdusa.blogspot.com/


BSE (Mad Cow) Update: Do Reports of sCJD Clusters Matter?

snip... see full text ;

http://cjdtexas.blogspot.com/


CJD QUESTIONNAIRE

http://cjdquestionnaire.blogspot.com/


CJD, they eye's have it and they could be stealing them from your loved one

http://www.mad-cow.org/dec99_news.html#bbb


Subject: RE-The Eyes Have It (cjd) and they could be stealing them from your loved one... "pay back time" Date: Sat, 16 Sep 2000 10:04:26 -0700 From: "Terry S. Singeltary Sr." Reply-To: Bovine Spongiform Encephalopathy To: BSE-L@uni-karlsruhe.de

######### Bovine Spongiform Encephalopathy #########

Greetings List Members,

I hate to keep kicking a madcow, but this still is very disturbing to me. Not only for the recipient of the cornea's, but as well, for the people whom would be operated on, using the same tools that were used to put those stolen cornea's in the recipient with. No history of this donor or his family (re-ffi), or anything would be known, using stolen organs and or tissue's. I just think this is not only wrong, but very dangerous to a great many other people, as this is one of the most infectious tissues of TSE's. It seems that this practice of stealing organ/tissue happens more than we think. Anyway, the family of the victim which had their cornea's stolen, are now suing. In the example I used with my Mother, if 3 months before, she would have been in a catastrophic accident (car wreck, whatever), no autopsy (for whatever reason), no family (for whatever reason), she lay in the morgue, and after 4 hours, they come steal the cornea's, lot of people could have been infected, just because of lack of medical history of donor/family. It may be hypothetical, but very real. We need to stop the spread of this disease.

kind regards, Terry S. Singeltary Sr., Bacliff, Texas USA ===========================================

Previous story--

Cadaver corneal transplants -- without family permission...

http://www.mad-cow.org/~tom/dec99_news.html#bbb


===============================================

Sept. 15, 2000, 11:39PM

Slain woman's family sues over missing eyes

By BILL MURPHY Copyright 2000 Houston Chronicle

The family of a woman who was stabbed to death last year has filed a lawsuit accusing the Lions Eye Bank of Houston of removing the woman's eyes without permission and inserting plastic discs in their place.

Daisy Diaz's relatives were horrified when they saw her body and noticed her eyes were missing, said their lawyer, Duncan Neblett III.

"They're a Catholic family," Neblett said. "They have strong beliefs about the body and burial. They were really upset by this."

Dorey Zidrow, the eye bank's spokeswoman, said she could not specifically discuss the Diaz case because it was in litigation. But Zidrow said a state law allows doctors to remove corneas -- the dime-sized lens near the eye's surface -- from a corpse without the family's permission.

The eye bank's usual procedure calls for removing the corneas, Zidrow said, but not the entire eyes.

"There are an awful lot of people who benefit from this program in the state of Texas," she said.

Diaz, 25, was stabbed to death in her apartment in the 400 block of Thornton in October. Her brother-in-law, 30-year-old Raudel Quiroz, is charged in the killing but has not been caught.

Neblett said authorities have told him Quiroz may have returned to his native Guatemala.

Neither Diaz nor her family had given permission to donate any of her organs, Neblett said.

Although state law allows corneas to be removed from corpses without first gaining the family's permission, they cannot be removed over the family's stated objection.

The eye bank is located at, and staffed by, the Baylor College of Medicine, and receives part of its funding from the Lions Club.

The Diaz lawsuit is the second such suit to be filed against the eye bank in recent years.

The family of Levi Perry Jr., a Houston teacher shot to death in MacGregor Park in 1994, also alleged in their suit that Perry's eyes were removed. The family was awarded $345,000 from the eye bank in April 1999.

http://www.chron.com/cs/CDA/story.hts/metropolitan/669555

==========================================================

THE LEGALITY OF STEALING ORGAN/TISSUE...

TEXAS STATUTES

Sec. 693.012. Removal of Corneal Tissue Permitted Under Certain Circumstances.

On a request from an authorized official of an eye bank for corneal tissue, a justice of the peace or medical examiner may permit the removal of corneal tissue if:

(1) the decedent from whom the tissue is to be removed died under circumstances requiring an inquest by the justice of the peace or medical examiner;

(2) no objection by a person listed in Section 693.013 is known by the justice of the peace or medical examiner; and

(3) the removal of the corneal tissue will not interfere with the subsequent course of an investigation or autopsy or alter the decedent's postmortem facial appearance.

Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989.

Note: This information includes legislation enacted through the 75th Congress. The 76th session of the Texas Legislature has concluded. The State of Texas has not yet made the new codes available to the public. Until they do, search the bill text for any changes or amendments.

Search 1999 Legislation for: 693.012 -------------------------------------------------------- TEXAS STATUTES Sec. 693.003. Consent Required in Certain Circumstances.

(a) A medical examiner or a person acting on the authority of a medical examiner may not remove a visceral organ unless the medical examiner or person obtains the consent of a person listed in Section 693.004.

(b) If a person listed in Section 693.004 is known and available within four hours after death is pronounced, a medical examiner or a person acting on the authority of a medical examiner may not remove a nonvisceral organ or tissue unless the medical examiner or person obtains that person's consent.

(c) If a person listed in Section 693.004 cannot be identified and contacted within four hours after death is pronounced and the medical examiner determines that no reasonable likelihood exists that a person can be identified and contacted during the four-hour period, the medical examiner may permit the removal of a nonvisceral organ or tissue.

Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989.

Note: This information includes legislation enacted through the 75th Congress. The 76th session of the Texas Legislature has concluded. The State of Texas has not yet made the new codes available to the public. Until they do, search the bill text for any changes or amendments.

Search 1999 Legislation for: 693.003 -------------------------------------------------------- PLEASE NOTE; the bottom would only pertain to those who know of the law. if you don't know about it, you cannot dispute, so in four hours, they can legally remove body organs, as long as they don't disfigure. and who is to know the difference? makes me wonder of some of my dead relatives, and if they were burried with their eye's and or any of their organs. This is very disturbing, if not for moral reasons, but for the risk of dangerous pathogens (human TSE's, etc.) to be transmitted. only time will tell, but i am very disturbed. these laws are not morally correct. They should be re-written as to they cannot so easily take your organs, with no one knowing. The Family or Victim, must consent. There should be some kind of research on donor/family medical history...TSS --------------------------------------------------------

Sec. 693.013. Persons Who May Object to Removal.

The following persons may object to the removal of corneal tissue:

(1) the decedent's spouse;

(2) the decedent's adult children, if there is no spouse;

(3) the decedent's parents, if there is no spouse or adult child; or

(4) the decedent's brothers or sisters, if there is no spouse, adult child, or parent.

Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989.

Note: This information includes legislation enacted through the 75th Congress. The 76th session of the Texas Legislature has concluded. The State of Texas has not yet made the new codes available to the public. Until they do, search the bill text for any changes or amendments.

Search 1999 Legislation for: 693.013 ------------------------------------------------------- to cover one's butt....

Sec. 693.014. Immunity From Damages in Civil Action.

(a) In a civil action brought by a person listed in Section 693.013 who did not object before the removal of corneal tissue, a medical examiner, justice of the peace, or eye bank official is not liable for damages on a theory of civil recovery based on a contention that the person's consent was required before the corneal tissue could be removed.

(b) Chapter 104, Civil Practice and Remedies Code, applies to a justice of the peace, medical examiner, and their personnel who remove, permit removal, or deny removal of corneal tissue under this subchapter as if the justice of the peace, medical examiner, and their personnel were state officers or employees.

Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989.

Note: This information includes legislation enacted through the 75th Congress. The 76th session of the Texas Legislature has concluded. The State of Texas has not yet made the new codes available to the public. Until they do, search the bill text for any changes or amendments.

Search 1999 Legislation for: 693.014

[[[as you can see, they knew it was wrong when they wrote the laws. or they would not have covered the rear-ends so well...TSS]]] --------------------------------------------------------- thanks again, kind regards, Terry S. Singeltary Sr.

############ http://mailhost.rz.uni-karlsruhe.de/warc/bse-l.html ############

----- Original Message ----- From: Terry S. Singeltary Sr. To: jgoodman@cber.fda.gov Sent: Friday, September 01, 2006 2:49 PM Subject: RE- FDA FORMS TASK FORCE ON HUMAN TISSUE SAFETY

http://www.microbes.info/forums/index.php?showtopic=375


JOHN CORNYN

TEXAS

UNITED STATES SENATE

WASHINGTON, DC 20510-4305

April 26,2005

Mr. Terry Singeltary P.O. Box 42 Bacliff, Texas 77518

Dear Mr. Singeltary:

In response to your recent request for my assistance, I have contacted the National Institutes ofHealth. I will write you again as soon as I receive a reply.

I appreciate having the opportunity to represent you in the United States Senate and to be of service in this matter.

Sincerely,

JOHN CORNYN United States Senator JC:djl

===============

JOHN CORNYN

TEXAS

UNITED STATES SENATE

WASHINGTON, DC 20510-4305

May 18,2005

Mr. Terry Singeltary P.O. Box 42 Bacliff, Texas 77518

Dear Mr. Singeltary:

Enclosed is the reply I received from the Department of Health and Human Services in response to my earlier inquiry on your behalf. I hope this will be useful to you. I appreciate having the opportunity to represent you in the United States Senate.

Thank you for taking time to contact me.

Sincerely,

JOHN CORNYN United States Senate JC:djl Enclosure

DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of HealthNational Institute of NeurologicalDisorders and Stroke NINDS Building 31, Room 8A52 31 Center Dr., MSC 2540 Bethesda, Maryland 20892-2540 Phone: 301-496-9746 Fax: 301-496-0296 Email: [log in to unmask]

May 10, 2005

The Honorable John Cornyn United States Senator Occidental Tower5005 LBJ Freeway, Suite 1150 Dallas, Texas 75244-6199

Dear Senator Cornyn:

Your letter to the National Institutes of Health (NIH) forwarding correspondence from Mr. Terry S. Singeltary, Sr., has been forwarded to me for reply. Mr. Singeltary is concerned about thepreservation of Creutzfeldt-Jakob disease (CJD) brain samples that have been maintained by theNational Institute of Neurological Disorders and Stroke (NINDS) Intramural Research programfor many years.

I am sorry to learn that Mr. Singeltary's mother died of CJD and can certainly understand hisdesire that any tissues that could help investigators unravel the puzzle of this deadly disease arepreserved. I hope he will be pleased to learn that all the brains and other tissues with potential tohelp scientists learn about CJD are, and will continue to be, conserved. (The tissues that arediscarded are those that have either decayed to an extent that renders them no longer appropriatefor research or those for which we do not have sufficient identification.)

The purpose of gathering these brains and tissues is to help scientists learn about CJD. To that end, some of the NINDS-held samples are distributed to investigators who can demonstrate thatthey have a compelling research or public health need for such materials. For example, sampleshave been transferred to NIH grantee Dr. Pierluigi Gambetti, who heads the National PrionDiseases Pathology Surveillance Center at Case Western Reserve University in Ohio and workswith the Centers for Disease Control and Prevention to monitor all cases of CJD in the UnitedStates. Dr. Gambetti studies the tissues to learn about the formation, physical and chemicalproperties, and pathogenic mechanisms of prion proteins, which are believed to be involved inthe cause of CJD. Samples have also been transferred to Dr. David Asher, at the U.S. Food andDrug Administration, for use in assessing a potential diagnostic test for CJD.

Page 2 - The Honorable John Cornyn

in closing, we know that donating organs and tissue from loved ones is a very difficult andpersonal choice that must often be made at the most stressful of times. We at the NINDS aregrateful to those stalwart family members who make this choice in the selfless hope that it willhelp others afflicted with CJD. We also know the invaluable contribution such donations maketo the advancement of medical science, and we are dedicated to the preservation of all of thetissue samples that can help in our efforts to overcome CJD.

I hope this information is helpful to you in responding to Mr. Singeltary. Sincerely,

Story C. Landis, Ph.D. Director, National Institute ofNeurological Disorders and Stroke

==================================

NIH says it will preserve CJD brains By STEVE MITCHELL

WASHINGTON, May 31 (UPI) -- The National Institutes of Health apparently has reversed its position on the fate of an invaluable collection of brains from people afflicted with a condition similar to mad cow disease, saying in a letter to a U.S. senator it will not destroy the collection.

An NIH official had told United Press International previously that the brain collection, which consists of samples from hundreds of people who died from the brain-wasting illness called Creutzfeldt Jakob disease, could be discarded if another entity does not claim them.

That sparked an outcry from patient-advocacy groups, consumer watchdogs and scientists, and the agency now appears to have backed away from that course.

"All the brains and other tissues with potential to help scientists learn about CJD are, and will continue to be, conserved," Story Landis, director of the National Institute of Neurological Disorders and Stroke, which oversees the brain collection, wrote in a May 10 letter to Sen. John Cornyn, R-Texas.

Cornyn had inquired about the status of the collection in April.

Last March, Eugene Major, acting director of the basic neuroscience program at the NIH, told UPI the useful portions of the collection had been doled out to scientists and the remaining samples had "very little remaining value" and could be destroyed.

Landis could not be reached for comment Tuesday. NINDS spokesman Paul Girolami told UPI he had been unable to locate her.

Scientists think the collection, which dates back to 1963, is invaluable for research on CJD and similar diseases and could even provide insight into treatments. There is no cure for CJD and patients typically die within a year after symptoms begin.

"Absolutely, the collection is worth keeping," Bruce Johnson, a former NIH scientist who said he had been told the collection would be destroyed in two years if no one took the samples from the agency, told UPI.

The Memorial Institute for Neurodegenerative Diseases Inc., a non-profit organization consisting of more than 40 researchers from several countries, offered to take the collection off of NIH's hands more than a year ago and so far has not heard anything from the agency, Harry Peery, MIND's executive director, told UPI.

CJD belongs to a group of incurable and fatal diseases collectively known as transmissible spongiform encephalopathies, or TSEs, that includes mad cow disease in cows, chronic wasting disease in deer and elk, and scrapie in sheep.

Variant CJD, or vCJD, is a relatively new TSE, which people can contract from consuming beef products infected with the mad cow pathogen.

Despite Landis' assurance the collection will be preserved, some family members of the patients who donated their brains to the NIH are still skeptical. This is because the wording Landis used in the letter leaves open the possibility that some brain samples are being destroyed.

"The tissues that are discarded are those that have either decayed to an extent that renders them no longer appropriate for research or those for which we do not have sufficient identification," Landis wrote.

"Which ones" are being destroyed? asked Terry Singeltary, who is involved with several CJD patient groups.

"With a system like this, they could destroy whatever and whenever they wanted, for whatever reason they wanted," Singeltary, whose mother died of CJD in 1997, told UPI.

"It's a perfect excuse to discard some suspicious tissue resembling vCJD or some atypical TSE related to animal TSEs in the USA," he added.

Although the collection includes samples from CJD patients as young as 16 that could make them candidates for possible vCJD, the brains have never been screened for evidence of the disease. The only confirmed vCJD case in the United States occurred in a Florida woman who is thought to have contracted the disease in England.

Johnson said he along with renowned CJD expert Paul Brown were in the process of sorting through the samples to match them up with patient identification documents until they both retired. Some of the samples may prove impossible to identify, he said, but he and Brown are the only ones familiar enough with the collection to organize it and neither has been asked back by the agency to aid in the identification process.

Steve Mitchell is UPI's Medical Correspondent. E-mail: [log in to unmask]

Copyright 2005 by United Press International. All Rights Reserved.

http://washingtontimes.com/

http://www.sciencedaily.com/

Wednesday, January 02, 2008

Risk factors for sporadic Creutzfeldt-Jakob disease

http://creutzfeldt-jakob-disease.blogspot.com/2008/01/risk-factors-for-sporadic-creutzfeldt.html


(Not to forget about the potential for some BSE cases to come from vaccinations containing pituitary-derived SRMs.)

TWA LITTLE minute

http://www.bseinquiry.gov.uk/files/yb/1988/06/10001001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/06/13010001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/06/14006001.pdf


COMMERCIAL IN CONFIDENCE

http://www.bseinquiry.gov.uk/files/yb/1988/09/06005001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/10/06005001.pdf


NOT FOR PUBLICATION

http://www.bseinquiry.gov.uk/files/yb/1988/11/01012001.pdf


http://www.bseinquiry.gov.uk/yb/1988/11/04003001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/04/00007001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/07/00007001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/09/00004001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/10/00003001.pdf


http://www.bseinquiry.gov.uk/files/yb/1989/01/04001001.pdf


http://www.bseinquiry.gov.uk/files/yb/1989/01/26007001.pdf


http://www.bseinquiry.gov.uk/files/yb/1989/01/30001001.pdf


http://www.bseinquiry.gov.uk/files/yb/1989/09/06011001.pdf


NON-LICENSED HUMAN TISSUE DEVICES WERE NOT COMMERCIALLY AVAILABLE

snip...

I was quite prepared to believe in unofficial pituitary hormones, also in the 1970's, whether as described by Dr. Little, or in other circumstances, for animal use.

snip...

The fact that there were jars of pituitaries (or extract) around on shelves is attested by the still potent 1943 pituitaries, described in Stockell Hartree et al. (J/RF/17/291) which had come from the lab. at Mill Hill. Having taken the trouble to collect them, they were not lightly thrown out...

http://www.bseinquiry.gov.uk/files/ws/s467bx.pdf


more on the 1968 medicine act, they forgot to follow

http://www.bseinquiry.gov.uk/files/yb/1989/01/30008001.pdf


Draft cover letter to product licence holders (considered by Human and Vet Medicines including deer)

http://www.bseinquiry.gov.uk/files/yb/1989/02/22008001.pdf


http://www.bseinquiry.gov.uk/files/yb/1989/02/22011001.pdf


(It was noted with concern that hormone extracts could be manufactured by a veterinary surgeon for administration to animals under his care without any Medicines Act Control.)

http://www.bseinquiry.gov.uk/files/yb/1988/06/08011001.pdf


http://www.bseinquiry.gov.uk/files/yb/1988/06/07010001.pdf


TWA LITTLE STATEMENT 331

http://www.bseinquiry.gov.uk/files/ws/s331.pdf


TSS

Tuesday, January 08, 2008

Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases

Tuesday, January 08, 2008 Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases Virus Res. 2007 Dec 27; : 18164506

Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases.

[My paper] Pawel P Liberski , Beata Sikorska , Jean-Jacques Hauw , Nicolas Kopp , Nathalie Streihenberger , Pierric Giraud , Herbert Budka , J W Boellaard , Paul Brown

Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease (GSS) and Fatal Familial Insomnia (FFI) are slow neurodegenerative disorders classified as transmissible spongiform encephalopathies (TSEs) or prion diseases, which appear in sporadic, hereditary or environmentally acquired forms. Tubulovesicular structures (TVS) are ultrastructural particles of unknown origin and chemical composition found in the brains of both animal and human forms of transmissible spongiform encephalopathies or prion diseases. In this paper, we report the results of a search for TVS in a total of 13 cases of sporadic Creutzfeldt-Jakob disease, three cases of Gerstmann-Sträussler-Scheinker disease, two cases of Fatal Familial Insomnia, and individual cases of familial, iatrogenic, and variant CJD (vCJD). TVS were found in all but one sporadic and one familial case of CJD. As controls, we examined 15 cases of Alzheimer's disease (AD), two cases of Pick's disease, and one case of multiple system atrophy. TVS were not present in any of these cases. This study confirms the TSE-specificity of TVS, the morphology of which suggests a possible pathogenetic role and relationship to recently described virion-like arrays of 25nm particles in scrapie-infected tissue cultures. http://lib.bioinfo.pl/auth:Brown,P

Neuroscience Cells infected with scrapie and Creutzfeldt-Jakob disease agents produce intracellular 25-nm virus-like particles ( infection neuroectodermal cultures virion ultrastructure prion amyloid retrovirus )

Laura Manuelidis *, Zhoa-Xue Yu, Nuria Banquero, and Brian Mullins Yale Medical School, 333 Cedar Street, New Haven, CT 06510

Communicated by Sheldon Penman, Massachusetts Institute of Technology, Cambridge, MA, December 11, 2006 (received for review October 10, 2006)

We had repeatedly found 25-nm-diameter virus-like particles in highly infectious brain fractions with little prion protein (PrP), and therefore we searched for similar virus-like particles in situ in infected cell lines with high titers. Neuroblastoma cells infected with the 22L strain of scrapie as well as hypothalamic GT cells infected with the FU Creutzfeldt-Jakob disease agent, but not parallel mock controls, displayed dense 25-nm virus-like particles in orthogonal arrays. These particles had no relation to abnormal PrP amyloid in situ, nor were they labeled by PrP antibodies that faithfully recognized rough endoplasmic reticulum membranes and amyloid fibrils, the predicted sites of normal and pathological intracellular PrP. Additionally, phorbol ester stimulated the production of abnormal PrP gel bands by >5-fold in infected N2a + 22L cells, yet this did not increase either the number of virus-like arrays or the infectious titer of these cells. Thus, the 25-nm infection-associated particles could not be prions. Synaptic differentiation and neurodegeneration, as well as retroviruses that populate the rough endoplasmic reticulum of neuroblastoma cells, were not required for particle production. The 25-nm particle arrays in cultured cells strongly resembled those first described in 1968 in synaptic regions of scrapie-infected brain and subsequently identified in many natural and experimental TSEs. The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid-protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions that induce late-stage PrP brain pathology.

---------------------------------------------------------------------------- ----

Author contributions: L.M. designed research; L.M., Z.-X.Y., N.B., and B.M. performed research; L.M., Z.-X.Y., and N.B. analyzed data; and L.M. wrote the paper.

The authors declare no conflict of interest.

*To whom correspondence should be addressed.

Laura Manuelidis, E-mail: laura.manuelidis@yale.edu

www.pnas.org/cgi/doi/10.1073/pnas.0610999104


http://www.pnas.org/cgi/content/abstract/0610999104v1


please see ;

http://info.med.yale.edu/neurosci/faculty/manuelidis_main.html


========================================

From: TSS Subject: Disease-specific particles without prion protein in prion diseases – phenomenon or epiphenomenon? Date: July 13, 2007 at 9:49 am PST

Disease-specific particles without prion protein in prion diseases – phenomenon or epiphenomenon?

P. P. Liberski**Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland; and Pawel P. Liberski, Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Czechoslowacka Street 8/10, PL 92-216 Lodz, Poland. Tel: +42-679-14-77; Fax: +42-679-14-77; E-mail: ppliber@csk.am.lodz.pl and P. Brown††Refired, Bethesda, Maryland, USA *Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland; and †Refired, Bethesda, Maryland, USA Pawel P. Liberski, Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Czechoslowacka Street 8/10, PL 92-216 Lodz, Poland. Tel: +42-679-14-77; Fax: +42-679-14-77; E-mail: ppliber@csk.am.lodz.pl P. P. Liberski and P. Brown (2007) Neuropathology and Applied Neurobiology 33, 395–397

Disease-specific particles without prion protein in prion diseases – phenomenon or epiphenomenon?

Abstract

The search for the cause of transmissible spongiform encephalopathies (TSEs) has a long and tortuous history. In a recent paper, 25-nm virus-like particles were identified that were consistently observed in cell cultures infected with Creutzfeldt-Jakob disease (CJD) and scrapie; they are similar to, or even identical with, the virus-like tubulovesicular structures (TVS)

found in experimental scrapie as early as in 1968, and subsequently in all naturally occurring and experimentally induced TSEs. These particles have been viewed with caution by the scientific community because of the unverified or uninterpretable record of virus-like structures reported over the years in TSEs. TVS are spherical or tubular particles of approximate diameter 25–37 nm. They are smaller than synaptic vesicles, but larger than many particulate structures of the central nervous system, such as glycogen granules. Their electron density is higher compared with synaptic vesicles, and in experimental murine scrapie, they form paracrystalline arrays. None of these observations distinguish between TVS as an entity critical to the infectious process, or as a highly specific ultrastructural epiphenomenon, but their consistent presence in all TSEs demands further research.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2990.2007.00867.x


Confusious is confused again ???

An epiphenomenon is a secondary phenomenon that occurs alongside a primary phenomenon.

Often, a causal relationship between the phenomena is implied: the epiphenomenon is a consequence of the primary phenomenon. In medicine, this relationship is typically not implied: an epiphenomenon may occur independently, and is merely called an epiphenomenon because it is not the primary phenomenon under study. (A side-effect is a specific kind of epiphenomenon that does occur as a consequence.)

In philosophy of mind, epiphenomenalism is the view that mental phenomena are caused by physical phenomena, and cannot cause anything themselves. It was probably first mentioned by T. H. Huxley in 1874.

Marvelous that the authors ignore the fact that Manuelidis et al first reported dense 25nm diameter particles (by field flow fractionation in 1992) in highly infectious brain fractions with little PrP. Unlike PrP, these viruslike particles have not been found in uninfected brains. Of course they are important to characterize. Though the authors seem to dismiss them as epiphenomena. Could the dense 25nm particles be the Phenomenon, with the PrP the Epiphenomenon ? which came first, the horse or the cart ???

TSS et al ;-)

BIOLOGICAL SCIENCES / NEUROSCIENCE Cells infected with scrapie and Creutzfeldt–Jakob disease agents produce intracellular 25-nm virus-like particles

Laura Manuelidis*, Zhoa-Xue Yu, Nuria Barquero, and Brian Mullins

Yale Medical School, 333 Cedar Street, New Haven, CT 06510

Communicated by Sheldon Penman, Massachusetts Institute of Technology, Cambridge, MA, December 11, 2006 (received for review October 10, 2006)

We had repeatedly found 25-nm-diameter virus-like particles in highly infectious brain fractions with little prion protein (PrP), and therefore we searched for similar virus-like particles in situ in infected cell lines with high titers. Neuroblastoma cells infected with the 22L strain of scrapie as well as hypothalamic GT cells infected with the FU Creutzfeldt–Jakob disease agent, but not parallel mock controls, displayed dense 25-nm virus-like particles in orthogonal arrays. These particles had no relation to abnormal PrP amyloid in situ, nor were they labeled by PrP antibodies that faithfully recognized rough endoplasmic reticulum membranes and amyloid fibrils, the predicted sites of normal and pathological intracellular PrP. Additionally, phorbol ester stimulated the production of abnormal PrP gel bands by >5-fold in infected N2a + 22L cells, yet this did not increase either the number of virus-like arrays or the infectious titer of these cells. Thus, the 25-nm infection-associated particles could not be prions. Synaptic differentiation and neurodegeneration, as well as retroviruses that populate the rough endoplasmic reticulum of neuroblastoma cells, were not required for particle production. The 25-nm particle arrays in cultured cells strongly resembled those first described in 1968 in synaptic regions of scrapie-infected brain and subsequently identified in many natural and experimental TSEs. The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid–protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions that induce late-stage PrP brain pathology.

infection neuroectodermal cultures virion ultrastructure prion amyloid retrovirus

---------------------------------------------------------------------------- ---- Author contributions: L.M. designed research; L.M., Z.-X.Y., N.B., and B.M. performed research; L.M., Z.-X.Y., and N.B. analyzed data; and L.M. wrote the paper. The authors declare no conflict of interest.

*To whom correspondence should be addressed. E-mail: laura.manuelidis@yale.edu

© 2007 by The National Academy of Sciences of the USA

http://www.pnas.org/cgi/content/abstract/104/6/1965?hits=10&RESULTFORMAT=&FIRSTINDEX=10&maxtoshow=&HITS=10&fulltext=manuelidis&searchid=1&resourcetype=HWCIT


Prospect A 25 nm virion is the likely cause of transmissible spongiform encephalopathies

Laura Manuelidis * Yale Medical School, New Haven, Connecticut 06510

email: Laura Manuelidis (laura.manuelidis@yale.edu)

*Correspondence to Laura Manuelidis, Yale Medical School, New Haven, CT 06510.

Funded by: NIH-NS12674 DOD-DAMD-17-03-1-0360

Keywords Creutzfeldt-Jakob disease • scrapie • BSE • viral particle • latent infection • prion pathology

Abstract The transmissible spongiform encephalopathies (TSEs) such as endemic sheep scrapie, sporadic human Creutzfeldt-Jakob disease (CJD), and epidemic bovine spongiform encephalopathy (BSE) may all be caused by a unique class of slow viruses. This concept remains the most parsimonious explanation of the evidence to date, and correctly predicted the spread of the BSE agent to vastly divergent species. With the popularization of the prion (infectious protein) hypothesis, substantial data pointing to a TSE virus have been largely ignored. Yet no form of prion protein (PrP) fulfills Koch's postulates for infection. Pathologic PrP is not proportional to, or necessary for infection, and recombinant and amplified prions have failed to produce significant infectivity. Moreover, the wealth of data claimed to support the existence of infectious PrP are increasingly contradicted by experimental observations, and cumbersome speculative notions, such as spontaneous PrP mutations and invisible strain-specific forms of infectious PrP are proposed to explain the incompatible data. The ability of many slow viruses to survive harsh environmental conditions and enzymatic assaults, their stealth invasion through protective host-immune defenses, and their ability to hide in the host and persist for many years, all fit nicely with the characteristics of TSE agents. Highly infectious preparations with negligible PrP contain nucleic acids of 1-5 kb, even after exhaustive nuclease digestion. Sedimentation as well as electron microscopic data also reveal spherical infectious particles of 25-35 nm in diameter. This particle size can accommodate a viral genome of 1-4 kb, sufficient to encode a protective nucleocapsid and/or an enzyme required for its replication. Host PrP acts as a cellular facilitator for infectious particles, and ultimately accrues pathological amyloid features. A most significant advance has been the development of tissue culture models that support the replication of many different strains of agent and can produce high levels of infectivity. These models provide new ways to rapidly identify intrinsic viral and strain-specific molecules so important for diagnosis, prevention, and fundamental understanding. J. Cell. Biochem. 100: 897-915, 2007. © 2006 Wiley-Liss, Inc.

---------------------------------------------------------------------------- ---- Received: 12 July 2006; Accepted: 13 July 2006 Digital Object Identifier (DOI)

http://www3.interscience.wiley.com/cgi-bin/abstract/112784723/ABSTRACT?CRETRY=1&SRETRY=0


doi:10.1016/0168-1702(92)90016-3 Copyright © 1992 Published by Elsevier Science B.V.

Analysis of Creutzfeldt-Jakob disease infectious fractions by gel permeation chromatography and sedimentation field flow fractionation

T. Sklaviadis1, R. Dreyer2 and Laura Manuelidis Yale University, School of Medicine, New Hauen, CT 06510, USA Received 17 June 1992; revised 3 September 1992; accepted 8 September 1992. Available online 5 November 2002.

Abstract

Gel permeation chromatography and sedimentation field flow fractionation (SF3) were used to further analyze highly infectious fractions from Creutzfeldt-Jakob disease (CJD) infected hamster brain. These analyses defined the relative molecular mass and physical size of the Creutzfeldt-Jakob disease (CJD) agent with greater precision than previously possible. Highly purified disaggregated fractions yielded single, homogeneous Gaussian peaks with both methods. The relevant analytical peaks contained protein-nucleic acid complexes with an Mrr of ˜ 1.5 × 107 daltons and a mean radius of ˜ 30 nm. The experimental evidence further solidifies the concept of an infectious agent that resembles a viral core rather than a simple protein.

Author Keywords: Scrapie; Creutzfeldt-Jakob Disease; Gel permeation chromatography; Sedimentation field flow fractionation; Agent radius; Molecular mass

1 Present address: Aristotle University of Thessaloniki, School of Health Sciences, Department of Pharmaceutical Sciences, Thessaloniki 54006, Greece.

2 Present address: Miles Laboratories MRC, 400 Morgan Lane, West Haven, CT 06516, USA.

Correspondence to: L. Manuelidis, Yale University, School of Medicine, 310 Cedar St., , New Haven, CT 06510, , USA.

http://www.sciencedirect.com/


1. Sklaviadis, T., Manuelidis, L. and Manuelidis E.E. (1986). Characterization of major peptides in Creutzfeldt-Jakob disease and scrapie. Proc. Natl. Acad. Sci. USA 83:6146-6150.

2. Manuelidis, L., Sklaviadis, T. and Manuelidis, E.E. (1987). Evidence suggesting that PrP is not the infectious agent in Creutzfeldt-Jakob disease. EMBO J 6:341-347.

3. Manuelidis, L., Tesin, D., Sklaviadis, T. and Manuelidis, E.E. (1987). Astrocyte gene expression in Creutzfeldt-Jakob disease. Proc. Natl. Acad. Sci. USA 84:5937-5941.

4. Manuelidis, L., Sklaviadis, T. and Manuelidis, E.E. (1987). On the origin and significance of scrapie associated fibrils. In: Court, L., Dormont, D., Brown, P., Kingbury, D.T. (eds) 2nd International Symposium of Unconventional Virus Diseases of the Central Nervous System. Masson, Paris, pp 489-507.

5. Sklaviadis, T.K., Manuelidis, L. and Manuelidis, E.E. (1989). Physical properties of the Creutzfeldt-Jakob disease agent. J. Virol. 63:1212-1222.

6. Murdoch, G.H., Sklaviadis, T., Manuelidis, E.E., Manuelidis, L. (1990). Potential retroviral RNAs in Creutzeldt-Jakob disease. J. Virol. 64:1477-1486.

7. Sklaviadis, T., Akowitz, A., Manuelidis, E.E., Manuelidis, L. (1990). Nuclease treatment results in high specific purification of Creutzfeldt-Jakob disease infectivity with a density characteristic of nucleic acid-protein complexes. Arch. Virol. 112: 215-229.

8. Akowitz, A., Sklaviadis, T., Manuelidis, E.E., Manuelidis, L. (1990). Nuclease-resistant polyadenylated RNAs of significant size are detected by PCR in highly purified Creutzfeldt-Jakob disease preparations. Microbial Pathogenesis 9:33-45.

9. Sklaviadis, T., Dreyer, R., Manuelidis, L.(1992) Analysis of Creutzfedt-Jakob disease infectious fractions by gel permeation chromatography and sedimentation field flow fractionation. Virus Research 26, 241-254.

10. Sklaviadis, T., Akowitz, A., Manuelidis, E.E., Manuelidis, L. (1993) Nucleic acid binding proteins in highly purified Creutzfeldt-Jakob disease preparations. Proc. Natl. Acad. Sci. USA, 90: 5713-5717.

11. Vizirianakis, J.S., Tsiftsoglou A., S., Sklaviadis, T. Developments in slow virus research: Implications of PrP protein involvement in cell growth and differentiation (1993), Bovine Spongiform Encephalopathy. Where are we now? Commision of the European Communities, 14-15 September 1993, Brussels

12. Akowitz, A., Sklaviadis, T., Manuelidis, L. (1994) Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob Disease. Nucl. Acids. Res., 22: 1101-1107.

13. Manuelidis, T. Sklaviadis, A. Akowitz, W. Fritch (1995) Viral particles are required for infection in neurodegenerative Creutzfeldt-Jakob disease Proc. Natl. Acad. Sci. USA , 92: 5124-5128.

14. Papaconstantinou, E., Karakiulakis, G., Roth, M., Dawson,M., Keyes, P., Papadopoulos,O.,Sklaviadis,T. (1999) Glycan alterations associated with bovine spongiform encephalopathy (Accepted in archives of biochemistry and biophysics)

15. S.Verghese-Nikolakaki, H. Mihaloudi, M. Polymenidou, M. Groschup, G. Papadopoulos, T. Sklaviadis (1999) Expression of the prion protein in the rat forebrain-, an immunohistochemical study. Neuroscience letters 272 9-12

16. S. Leontidis, V. Psychas, S. Argyroudis, A. Giannti-Stefanou, E. Paschaleri-Papadopoulou, T. Manousis, T. Sklaviadis (1999) An overeleven year survey of neurologic diseases of ruminats with special reference to transmissible spongiform encephalopathies (TSEs) in Greece (Accepted for publication Journal of Veterinary Medicine)

17. T. Manousis, M. Sachsamanoglou, P. Toumazos, S. Vergehese-Nikolakaki, O. Papadopoulos, T. Sklaviadis (1999) Western blot detection of PrP Sc in Cyprus sheep with natural scrapie (Accepted for publication The Veterinary Journal)

18. Vassilikioti ,O. Papadopoulos,T. Sklaviadis (1999) Reverse transriptase activity in BSE infectious fractions. (Submitted)

19. Sachsamanoglou, M., Lolis, E., Sklaviadis, T. (1999) Thermostable and chemically induced intermediate conformations of human PrP protein (submitted)

20. T. Manousis, P. Keyes, I. Dexter, R. Green, M. Sachsananoglou, M. Dawson, S. verghese-Nikolakaki, O. Papadopoulos, T. Sklaviadis (1999) Characterization of the murine BSE infectious agent (Submitted Journal of General Virology)

http://www.pharm.auth.gr/prion/Publications.htm


TSS

Wednesday, January 02, 2008

Risk factors for sporadic Creutzfeldt-Jakob disease

Wednesday, January 02, 2008 Risk factors for sporadic Creutzfeldt-Jakob disease

FURTHER INTO THIS STUDY ;

Risk factors for sporadic Creutzfeldt-Jakob disease

snip...

DISCUSSION

We observed and increased risk for sCJD associated with a reported lifetime history of ever having had surgery. However, contrary to what might have been expected if this association was causal, risk did not appear to increase with the total number of operations reported. The increase in risk associated with having had surgery was restricted to the category "other surgery." This category contained a range of procedures from minor, the most common of which was skin stitches, through to more complicated operations, such as urological and cardiovascular procedures. The association between sCJD and any surgery was reduced when those "other" operations likely to be most prone to recall bias and misclassification were excluded, and the association largely disappeared when the whole of the "other surgery" category was excluded.

The association between any surgery and sCJD appeared strongest for operations in the preceding 10 to 20 years. This is compatible with the deduced incubation periods form previous neurosurgical transmissions (12-28 months) and from one of the two transmissions from corneal transplants (18 and 320 months).[7] "Other surgery" further back in the past was also associated with sCJD. Longer incubation periods would be expected from more peripheral routes of surgical transmission. However, differential recall bias for respondents for cases and control subjects is also a possible explanation for these observations. Kondo and Kuroiwa [28] describe an association between any surgery within 5 years of disease onset and risk for sCJD; however, they did not examine any other time period. The mean time between first surgery and death was 29 (standard deviation, 17.4) years in the Australian study, and the median time between first gynecological surgery and onset was 21 (range, 0-60) years in the European study. [16] [17]

Although our results appear broadly consistent with two previous large case-control studies from Australia and Europe, some important differences are apparent when examined in detail.[16][17] All reported an increased risk for sCJD associated with "any surgery" and with "other surgery." Whereas in this study there was some evidence that both eye and orthopedic surgeries within the preceding 20 years were associated with increased risk for sCJD, we found no evidence of an association of risk with other categories of surgery. The Australian study found increased risk associated with a range of surgical procedures (carpal tunnel, eye, heart, hemorrhoid, gall bladder, hernia, hysterectomy, varicose vein), and the European study found a small increased risk associated with gynecological surgery (and reduced risk associated with tonsillectomy and appendectomy). Other smaller studies have reported varying findings relating to medical risk and sCJD, but have lacked power and/or been subject to bias. [27-32]

All these studies are susceptible to a number of potential sources of bias. In the Australian and European studies, interviews were performed with relatives of cases, but directly with control subjects, which may have resulted in systematic differences in the quality of information available for cases and control subjects.[16][17] To minimize this problem, we interviewed relatives of control subjects rather than control subjects themselves to "match" the approach used to obtain data on cases. Nevertheless, we cannot exclude the possibility that recall bias accounts for the differences we observed between cases and control subjects, particularly for "other surgery." Relatives of cases may make more effort to recall all surgical procedures, even the most minor, than relatives of control subjects. On the other hand, the analysis of anatomic categories rather than specific procedures could dilute the association of a particular high-risk procedure with CJD and lead to failure to detect that association.[33] Furthermore, relatives were asked to recall procedures that occurred many years in the past. This is likely to have resulted in some data from cases and control subjects being misclassified. If the tendency to misclassification was similar for cases and control subjects, this could have obscured real causal associations. Response bias is a possibility because no risk factor information was obtained for 72 cases who were, on average, 3 years older than the 431 cases with risk factor data.

The relationship of the respondent to the case or control subject may also contribute to bias if systematically different between cases and control subjects. Respondent types were similar for those born before 1950, but for those born after 1950, 25% of the control respondents were parents compared with none of the case respondents. Restricting the analysis to those born before 1950 did not alter our findings (data not shown). Other potential sources of bias relating to the NatCen controls have been detailed previously.[22]

Examining a large number of sCJD cases, we found no evidence of temporal-geographic links suggestive of onward transmission through use of contaminated instruments during neurosurgery or gynecological surgery. Given the distribution of infectivity in sCJD and the resistance of the infectious agent to decontamination, we might have expected to find evidence of iatrogenic transmission via neurosurgery in this group of cases classified as sCJD. However, in addition to the negative results here, there have been no reported instances of iatrogenic transmission of sCJD through neurosurgery or through stereotactic electrode use since the 1970s.[7] Possible explanations for this are that there have been no further transmissions through neurosurgery, that we have failed to identify them, or that transmission is episodic.[34] Alternatively, perhaps, decontamination has improved sufficiently to prevent transmission occurring. Since the early 1980s in the United Kingdom, it has been recommended that neurosurgical instruments used on people with known CJD should not be reused. However, how strictly this has been adhered to is unknown, and transmission from those incubating the disease certainly remains a possibility. The establishment of further guidance in the late 1980s aimed to reduce this possibility.[35][36]

We may have missed some potential sources of iatrogenic transmission for a variety of reasons, including referral to other centers in the United Kingdom and atypical presentations being unrecognized as CJD. In addition, we only had general practitioner records in a small proportion of cases, having to rely on reported surgical histories from relatives for most cases. Because a proportion of the operations were performed relatively recently, there may not have been a long enough period of follow-up to detect cases of transmission. However, given that the observed neurosurgical transmissions had incubation periods of 15 to 28 months and the 16-year period examined, we would expect to have identified any neurosurgical transmissions that occurred in the first 10 to 12 years of that period. Also, some people incubating the disease may have died of competing causes, for example, from cancer, before symptoms of CJD had developed.

It is perhaps not surprising that we did not find evidence of transmission of sCJD through gynecological surgical procedures. Although to our knowledge, infectivity has not been tested for in gynecological tissues (ovary and nongravid uterus) other than placenta in humans, cattle, sheep, or goats,[37] these tissues would not be expected to contain high infectivity titers. Also, if this were an important route of transmission, an excess of female sCJD cases might be expected. The female/male ratio over the study period in the United Kingdom was 1.08: 1.

Our data suggest that it is unlikely that a high proportion of UK sCJD cases are the result of transmission during surgery. However, we cannot exclude the possibility that such transmission occurs occasionally. We observed an increased risk for sCJD associated with reported surgical history, but this could be because of recall bias. We did not find any convincing individual links of sCJD cases related to surgery. However, it is important to determine whether the increased risk

associated with reported surgical history reflects a causal association or recall bias. A study based on accurate surgical histories obtained from medical records is underway. In the meantime, decontamination and public health guidance should be followed, [34-36] and efforts to imporve decontamination of surgical instruments are paramount.

Acknowledgements. ...snip...end...TSS

http://www3.interscience.wiley.com/cgi-bin/fulltext/117861913/main.html,ftx_abs


ALSO, some additional information on the UK export history of mad cow tainted pharmaceutical products as follows ;

10 January 1990

COMMERCIAL IN CONFIDENCE

NOT FOR PUBLICATION

COMMITTEE ON SAFETY OF MEDICINES WORKING PARTY ON BOVINE SPONGIFORM ENCEPHALOPATHY

SURGICAL CATGUT SUTURES

2.1 At the first meeting of the Working Party on Bovine Spongiform Encephalopathy on 6 September 1989, detailed consideration was given to XXXXX Surgical Catgut. This arose from the Company's response to the Letter to Licence Holders, indicating that the bovine small intestine source material was derived from UK cattle, unlike 8 other licenced catgut sutures. In contrast XXXXX Surgical Catgut was stated to hold over 90% share of the market for catgut sutures, and to constitute approximately 83% of all sutures used in U.K.

IMPORTS OF SUTURES FROM THE KNOWN BSE COUNTRY;

3006.10.0000: STERILE SURGICAL CATGUT, SIMILAR STERILE SUTURE MATERIALS AND STERILETISSUE ADHESIVES FOR SURGICAL WOUND CLOSURE; AND SIMILAR STERILE MATERIAL

U.S. Imports for Consumption: December 1998 and 1998 Year-to-Date (Customs Value, in Thousands of Dollars) (Units of Quantity: Kilograms)

<--- Dec 1998 ---> <--- 1998 YTD --->

Country Quantity Value Quantity Value

=================================================================

WORLD TOTAL . . . . . . . 10,801 3,116 143,058 40,068

Belgium . . . . . . . . . --- --- 107 14 France . . . . . . . . . 81 49 2,727 1,132 Switzerland . . . . . . . --- --- 1,357 1,693 United Kingdom . . . . . 1,188 242 35,001 5,564

U.S. Imports for Consumption: December 1998 and 1998 Year-to-Date Subheading 300210: ANTISERA AND OTHER BLOOD FRACTIONS, AND MODIFIED IMMUNOLOGICAL PRODUCTS

3002.10.0010: HUMAN BLOOD PLASMA

snip... see full text ;

http://www.mad-cow.org/00/jul00_dont_eat_sheep.html#hhh


BOTTOM LINE $$$

(Adopted by the International Committee of the OIE on 23 May 2006)

11. Information published by the OIE is derived from appropriate declarations made by the official Veterinary Services of Member Countries. The OIE is not responsible for inaccurate publication of country disease status based on inaccurate information or changes in epidemiological status or other significant events that were not promptly reported to the Central Bureau, ......

http://www.oie.int/eng/Session2007/RF2006.pdf


THE only difference between the UK poisoning the globe, and the USA, it is now legal with GWs and OIEs BSE MRR policy ;

IT's O.K. to poison 3rd world countries ;

http://www.bseinquiry.gov.uk/files/yb/1994/05/20002001.pdf


On 20 February 1990, Dr Pickles wrote to Ms Verity (APS/CMO). Dr Picklesí minute included the following:

1. Mr Meldrum is arguing that MAFF have already taken all the necessary and responsible steps to warn importing countries of the BSE dangers in UK meat and bone meal. Yet the action taken so far overseas suggest the message has not got through, or where it has this has been late. The first nation that woke up to the danger did so a year after our own feed ban. It seems even now several EC countries neither ban our imports or the general feeding of ruminant protein. It also seems the OIE and CVO have yet to inform the rest of the world.

2. I do not see how this can be claimed to be responsible. We do not need an expert group of the Scientific Veterinary Committee to tell us British meat and bone meal is unsafe for ruminants. I fail to understand why this cannot be tackled from the British end which seems to be the only sure way of doing it, preferably by banning exports. As CMO says in his letter of 3 January surely it is short sighted for us to risk being seen in future as having been responsible for the introduction of BSE to the food chain in other countries.[79]

http://www.bse.org.uk/dfa/dfa25.htm

PLEASE SEE CORRECT URL HERE ;

http://www.bseinquiry.gov.uk/files/yb/1990/02/20010001.pdf


http://www.mad-cow.org/00/jul00_dont_eat_sheep.html#hhh


BSE: SVC - 15 FEBRUARY 1990

snip...

I am concerned at the possible ban on the export of glands and organs for pharmaceutical purposes. No doubt you will be liaising with Brian Taylor to determine what products are being exported for these purposes and whether responsibility falls to DoH or ourselves.

Like you, I would prefer to avoid a further Commission Decision covering exports of bovine offals since it removes some of the flexibility that we now enjoy.

K C Medlrum 19 February 1990

http://www.bseinquiry.gov.uk/files/yb/1990/02/19007001.pdf


We decided NOT to recommend that exports for pharmaceutical products etc be similarly stopped because it is less likely that these would find their way onto the human consumption market, and in these circumstances it seemed unjustifiable to propose a ban on the trade, particularly without consultation. ...

http://www.bseinquiry.gov.uk/files/yb/1990/02/19008001.pdf


IT looks as if the SVC will want to discuss this again on 7/8th March. DOES it need someone from CPMP to tell the SVC to mind their own business. IF they persist in discussing it, we may need to have a DH representative at the meeting. IF the SVC convince themselves there is a problem with pharmaceuticals sourced from bovine ingredients in the UK, there is no telling what a mess they might be able to cause for our pharmaceutical manufacturers, as they have done for our beef industry. ...

http://www.bseinquiry.gov.uk/files/yb/1990/02/20003001.pdf


CONFIDENTIAL

The By-Products Problem

http://www.bseinquiry.gov.uk/files/yb/1990/07/00005001.pdf


NOT FOR PUBLICATION

COMMERCIAL IN CONFIDENCE

COMMITTEE ON THE SAFETY OF MEDICINES

snip...

Comment- It is known that British Bone Meal has been exported to the Netherlands and the USA. It is possible that it may have been used to compound animal feed stuffs, which may have been used for cattle. The use of ruminant protein has NOT been banned in the USA. The Company have not addressed the issue of ensuring that source cattle have not been fed ruminant protein, and that feeding practices are recorded and certified.

http://www.bseinquiry.gov.uk/files/yb/1990/10/00005001.pdf


Subject: BSE--U.S. 50 STATE CONFERENCE CALL Jan. 9, 2001 Date: Tue, 9 Jan 2001 16:49:00 -0800 From: "Terry S. Singeltary Sr." Reply-To: Bovine Spongiform Encephalopathy To: BSE-L@uni-karlsruhe.de

Bovine Spongiform Encephalopathy

Greetings List Members,

I was lucky enough to sit in on this BSE conference call today and even managed to ask a question. that is when the trouble started.

I submitted a version of my notes to Sandra Blakeslee of the New York Times, whom seemed very upset, and rightly so.

"They tell me it is a closed meeting and they will release whatever information they deem fit. Rather infuriating."

And I would have been doing just fine, until I asked my question. I was surprised my time to ask a question came so quickly.

(understand, these are taken from my notes for now. the spelling of names and such could be off.)

[host Richard Barns] And now a question from Terry S. Singeltary of CJD Watch.

[TSS] Yes, Thank You. U.S. cattle - what kind of guarantee can you give for serum or tissue donor herds?

[no answer, you could hear in the background, mumbling and "We can't. Have him ask the question again."]

[host Richard] Could you repeat the question?

[TSS] U.S. cattle..what kind of guarantee can you give for serum or tissue donor herds?

[not sure whom ask this] What group are you with?

[TSS] CJD Watch, my Mom died from hvCJD and we are tracking CJD world-wide.

[not sure who is speaking] Could you please disconnect Mr. Singeltary

[TSS] You are not going to answer my question?

[not sure whom speaking] NO

From this point, I was still connected, got to listen and tape the whole conference. at one point someone came on, a woman, and ask again;

[unknown woman] What group are you with?

[TSS] CJD Watch and my Mom died from hvCJD We are trying to tract down CJD and other human TSE's world wide. I was invited to sit in on this from someone inside the USDA/APHIS and that is why I am here. Do you intend on banning me from this conference now?

At this point the conference was turned back up, and I got to finish listening. They never answered or even addressed my one question, or even addressed the issue. BUT, I will try and give you a run-down for now, of the conference.

IF I were another Country, I would take heed to my notes, BUT PLEASE do not depend on them. ask for transcript from:

RBARNS@ORA.FDA.GOV 301-827-6906

He would be glad to give you one ;-)

snip...end

http://www.fda.gov/ohrms/dockets/dailys/03/Jan03/012403/8004be07.html


----- Original Message ----- From: "Terry S. Singeltary Sr." To: Sent: Sunday, December 16, 2007 3:52 PM Subject: [CJD-L] Risk factors for sporadic Creutzfeldt-Jakob disease

Published Online: 11 Dec 2007 Copyright © 2007 American Neurological Association Original Article

Risk factors for sporadic Creutzfeldt-Jakob disease

Hester J. T. Ward, FFPH 1 *, Dawn Everington, MSc 1, Simon N. Cousens, MA 2,Blaire Smith-Bathgate, RGN 1, Michelle Gillies, MRCP 1, Katy Murray, MRCP 1,Richard S. G. Knight, FRCPE 1, Peter G. Smith, DSc 2, Robert G. Will, FRCP 11National Creutzfeldt-Jakob Disease Surveillance Unit, University ofEdinburgh, Western General Hospital, Edinburgh, United Kingdom2Department of Epidemiology and Population Health, London School of Hygieneand Tropical Medicine, London, United Kingdomemail: Hester J. T. Ward (h.ward@ed.ac.uk)*Correspondence to Hester J. T. Ward, National CJD Surveillance Unit,Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, United KingdomFunded by:Department of Health; Grant Number: 121/7400Scottish Executive Health Department; Grant Number: R39924

Abstract

Objective

Although surgical transmission of Creutzfeldt-Jakob disease (CJD) has been demonstrated, these iatrogenic cases account for only a small proportion of all CJD cases. The majority are sporadic CJD (sCJD) cases of unknown cause. This study investigated whether some cases classified as sCJD might have an unrecognized iatrogenic basis through surgical or other medical procedures

Methods

This study compared medical risk factors from 431 sCJD cases referred 1998 to 2006 with 454 population control subjects. Possible geographic and temporal links between neurological and gynecological operations in 857 sCJD cases referred from 1990 to 2006 were investigated

Results

A reported history of ever having undergone surgery was associated with increased risk for sCJD (odds ratio, 2.0; 95% confidence interval, 1.3-2.1;p = 0.003). Increased risk was not associated with surgical categories chosen a priori but was confined to the residual category other surgery, in which the increase in risk appeared most marked for three subcategories: skin stitches, nose/throat operations, and removal of growths/cysts/moles. No convincing evidence was found of links (same hospital, within 2 years) between cases undergoing neurosurgery or gynecological surgery

Interpretation

It is unlikely that a high proportion of UK sCJD cases are the result of transmission during surgery, but we cannot exclude the possibility that such transmission occurs occasionally. A study based on accurate surgical histories obtained from medical records is required to determine whether the increased risk associated with reported surgical history reflects a causal association or recall bias.

Ann Neurol 2007--------------------------------------------------------------------------------

Received: 24 May 2007; Revised: 5 September 2007; Accepted: 1 October 2007

Digital Object Identifier (DOI)10.1002/ana.21294 About DOIAdditional Material

http://www3.interscience.wiley.com/cgi-bin/abstract/117861913/ABSTRACT?CRETRY=1&SRETRY=0


TSS

Creutzfeldt-Jakob Disease, Prion Protein Gene Codon 129VV, and a Novel PrPSc Type in a Young British Woman

Wednesday, January 02, 2008 Creutzfeldt-Jakob Disease, Prion Protein Gene Codon 129VV, and a Novel PrPSc Type in a Young British Woman Creutzfeldt-Jakob Disease, Prion Protein Gene Codon 129VV, and a Novel PrPSc Type in a Young British Woman

Simon Mead, PhD, MRCP; Susan Joiner, MSc; Melanie Desbruslais, BSc; Jonathan A. Beck, BSc; Michael O’Donoghue, PhD; Peter Lantos, FRCP; Jonathan D. F. Wadsworth, PhD; John Collinge, FRS

Arch Neurol. 2007;64(12):1780-1784.

Background Variant Creutzfeldt-Jakob disease (vCJD) is an acquired prion disease causally related to bovine spongiform encephalopathy that has occurred predominantly in young adults. All clinical cases studied have been methionine homozygotes at codon 129 of the prion protein gene (PRNP) with distinctive neuropathological findings and molecular strain type (PrPSc type 4). Modeling studies in transgenic mice suggest that other PRNP genotypes will also be susceptible to infection with bovine spongiform encephalopathy prions but may develop distinctive phenotypes.

Objective To describe the histopathologic and molecular investigation in a young British woman with atypical sporadic CJD and valine homozygosity at PRNP codon 129.

Design Case report, autopsy, and molecular analysis.

Setting Specialist neurology referral center, together with the laboratory services of the MRC [Medical Research Council] Prion Unit.

Subject Single hospitalized patient.

Main Outcome Measures Autopsy findings and molecular investigation results.

Results Autopsy findings were atypical of sporadic CJD, with marked gray and white matter degeneration and widespread prion protein (PrP) deposition. Lymphoreticular tissue was not available for analysis. Molecular analysis of PrPSc (the scrapie isoform of PrP) from cerebellar tissue demonstrated a novel PrPSc type similar to that seen in vCJD (PrPSc type 4). However, this could be distinguished from the typical vCJD pattern by an altered protease cleavage site in the presence of the metal ion chelator EDTA.

Conclusions Further studies will be required to characterize the prion strain seen in this patient and to investigate its etiologic relationship with bovine spongiform encephalopathy. This case illustrates the importance of molecular analysis of prion disease, including the use of EDTA to investigate the metal dependence of protease cleavage patterns of PrPSc.

Author Affiliations: MRC [Medical Research Council] Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, London, England (Drs Mead, Wadsworth, and Collinge; Mss Joiner and Desbruslais; and Mr Beck); and Institute of Psychiatry, King's College London (Dr Lantos). Dr O’Donoghue is now with the Department of Clinical Neurology, Nottingham University Hospitals NHS [National Health Service] Trust, Nottingham, England.

http://archneur.ama-assn.org/cgi/content/short/64/12/1780


Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States

http://cjdusa.blogspot.com/


http://creutzfeldt-jakob-disease.blogspot.com/


CJD QUESTIONNAIRE

http://cjdquestionnaire.blogspot.com/


TSS